Caprihans India Limited is a leading Indian manufacturer of specialized pharmaceutical packaging solutions. Operating as a subsidiary of **Bilcare Limited**, the company has recently undergone a massive structural transformation to integrate global manufacturing standards and high-barrier product capabilities. The company serves as a critical partner to global and domestic pharmaceutical giants, providing primary packaging that ensures the integrity of sensitive drug formulations. --- ### **Strategic Transformation & Corporate Integration** The company’s current trajectory is defined by the **March 27, 2023**, acquisition of the **Pharma Packaging Innovation (PPI)** division from its parent, **Bilcare Limited**, for **Rs. 213 Crores**. This "slump sale" consolidated the group’s pharmaceutical packaging expertise under one roof. * **Unified Operations:** The company has integrated Bilcare’s Quality Management System (QMS), manufacturing processes, and product specifications to offer a seamless global standard. * **Global Expansion:** In **September 2024**, the company incorporated **Bilcare Research GmbH** in **Frankfurt, Germany**. This 100% subsidiary serves as the beachhead for expanding market share in Europe and North America. * **Administrative Consolidation:** To improve operational synergy, the Registered Office was shifted from **Mumbai** to **Pune** in **July 2024**. --- ### **Manufacturing Footprint & Infrastructure Modernization** Caprihans is currently optimizing its manufacturing base in Maharashtra to improve productivity and reduce overheads. | Facility Location | Status & Strategic Role | | :--- | :--- | | **Pune (Shiroli)** | Registered Office and state-of-the-art integrated facility; features a **2.6 MW Solar Power unit** for energy cost optimization. | | **Nashik (Satpur)** | Integrated manufacturing facility focused on film extrusion and coating. | | **Taloja (Ambernath)** | New facility at **ESR Industrial & Logistics Park**, operational as of **September 01, 2024**. | | **Thane (Wagle Estate)** | **Operations ceased on January 27, 2025**. The site was monetized to fund relocation and debt reduction. | **Asset Monetization:** The company executed a "Deed of Assignment" for its Thane lease-hold land for **Rs. 75 Crores**, recording a profit of **Rs. 15.31 Crores**. These proceeds were strategically deployed to repay long-term debt and cover one-time relocation expenses to the modern Taloja site. --- ### **Product Portfolio & Innovation Pipeline** The company operates in the **Pharma Packaging Solutions** segment, focusing on high-performance materials that provide barriers against moisture, oxygen, odor, and contamination. * **Core Products:** * **Blister Packaging:** Rigid **PVC** and **PVdC** coated films known for dimensional stability and heat resistance. * **High-Barrier Solutions:** **Alu-Alu foils**, **lid foils**, and **Aclar** laminates for sensitive APIs and biologics. * **Specialized PVC Films:** Includes **anti-static** films for electronics, **UV-stabilized** films for automotive grades, and **REACH/RoHS** compliant films for regulated international markets. * **Value-Added Technology:** Integration of **tamper evidence**, **track-and-trace serialization**, **anti-counterfeit printing**, and **QR code-enabled** patient information. * **Sustainability Initiatives:** R&D is focused on **halogen-free** blister films, **recyclable mono-material** solutions, and **solvent-free** coating processes to meet **Extended Producer Responsibility (EPR)** norms. --- ### **Research & Development (R&D) Capabilities** Caprihans maintains **DSIR-recognized** in-house R&D units. The **Thane R&D Centre** is being relocated to the **ESR Taloja** facility to enhance innovation throughput. **R&D Expenditure (FY 2024-25):** | Unit | Capital (₹ Cr) | Revenue (₹ Cr) | Total (₹ Cr) | | :--- | :--- | :--- | :--- | | **Pune Unit** | **0.05** | **0.99** | **1.04** | | **Nashik Unit** | **-** | **0.80** | **0.80** | | **Thane Unit** | **-** | **0.15** | **0.15** | | **Total** | **0.05** | **1.94** | **1.99** | --- ### **Financial Performance & Capital Restructuring** The company is executing a promoter-led deleveraging program to stabilize its balance sheet following the PPI acquisition. **Key Financial Metrics:** | Metric | FY 2024-25 (Cr) | FY 2023-24 (Cr) | | :--- | :--- | :--- | | **Total Revenue from Operations** | **Rs. 737.85** | **Rs. 694.53** | | **Domestic Revenue (India)** | **Rs. 522.69** | **Rs. 501.69** | | **Export Revenue (Outside India)** | **Rs. 215.16** | **Rs. 192.84** | **Capital Infusion & Deleveraging:** * **Warrant Issuance:** In **November 2024**, the company approved **4,800,000** warrants at **Rs. 200** each to **Bilcare Limited**, aggregating **Rs. 96 Crores**. * **Promoter Holding:** Following progressive conversions, the promoter's shareholding reached **57.81%** by **March 2026**. * **Proceeds Utilization:** **Rs. 49.65 Crores** was used to redeem **0.1%** Preference Shares; **Rs. 25 Crores** was allocated to working capital. * **Debt Refinancing:** A consortium led by **The Cosmos Co-operative Bank** sanctioned a **Rs. 570 Crore** term loan (8-year tenure) and **Rs. 50 Crore** in working capital facilities. --- ### **Operational Standards & Compliance** The company adheres to stringent global regulatory frameworks required for primary pharmaceutical packaging: * **Certifications:** **ISO 15378:2017** (Pharma primary packaging), **ISO 14001:2015** (Environmental), and **ISO 45001:2018** (Health & Safety). * **Regulatory Alignment:** Manufacturing systems align with **EU**, **U.S. FDA**, and **WHO GMP** requirements. * **Efficiency Gains:** Recent investments in **AC drives** for cooling systems have yielded energy savings of **₹17.7 Lakhs per year**. --- ### **Risk Factors & Mitigation Strategies** #### **1. Legacy Financial Liabilities** The company assumed **Rs. 109.60 Crores** in **Public Fixed Deposit (PFD)** liabilities from Bilcare Limited. * **Status:** The liability was aggressively reduced to **Rs. 18.50 Crores** by **December 31, 2025**, with equivalent funds earmarked in escrow for final liquidation. #### **2. Credit & Asset Risks** * **Exceptional Provisions:** A provision of **Rs. 19.84 Crores** was recorded in **FY 2024-25** due to recovery uncertainties regarding Inter Corporate Deposits (ICD) and debtors from **Anax Industries Limited**. * **Labour Costs:** An exceptional charge of **Rs. 1.72 Crores** was recognized in late 2025 due to new **Labour Code** wage definitions affecting gratuity. #### **3. Market & Commodity Volatility** * **Raw Materials:** High sensitivity to **Resin** prices, which fluctuate based on global **crude oil** trends. * **Currency Exposure:** Significant export-import activity creates exposure to **USD** fluctuations. A **5%** shift in exchange rates impacts PBT by approximately **Rs. 7.32 Lacs**. * **Substitution Risk:** The **PVDC** market is under stress from alternative materials, requiring the company to pivot toward its new **halogen-free** and **recyclable** product lines. #### **4. Governance & Compliance** * The company has addressed previous non-compliance issues, including a **1-day delay** in filing related party transactions and a temporary shortfall in Board composition (corrected to the mandated **6 directors**).